CD28 and neoplasm: To overcome this problem, Ankri et al. and others have designed so-called switch receptors that comprise for example the extracellular domain of PD-1 fused to intracellular CD28 sequences and sustain CD28 signaling in the immune-suppressive tumor microenvironment [25, 47, 48].